{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:50:11Z","timestamp":1791985811545,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.euroneuro.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T19:05:33Z","timestamp":1456686333000},"page":"1062-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo"],"prefix":"10.1016","volume":"26","author":[{"given":"David S.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Hayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Reines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.02.013_bib1","doi-asserted-by":"crossref","DOI":"10.1185\/03007995.2016.1146663","article-title":"A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan","author":"Asakura","year":"2016","journal-title":"Curr. Med. Res. Opin"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib2","article-title":"Long-term administration of escitalopram in patients with social anxiety disorder in Japan","author":"Asakura","year":"2016","journal-title":"Neuropsychiatric Disease Treat."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study","volume":"10","author":"Asakura","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1K089","article-title":"Escitalopram therapy for major depression and anxiety disorders","volume":"41","author":"Baldwin","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/YIC.0b013e3282f4224a","article-title":"Efficacy and tolerability of second-generation antidepressants in social anxiety disorder","volume":"23","author":"Hansen","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/cap.2007.0007","article-title":"An open-label trial of escitalopram in children and adolescents with social anxiety disorder","volume":"17","author":"Isolan","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder. Randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1185\/03007990802622726","article-title":"Escitalopram in the treatment of major depressive disorder: a meta-analysis","volume":"25","author":"Kennedy","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib11","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMsa043266","article-title":"Prevalence and treatment of mental disorders, 1990 to 2003","volume":"352","author":"Kessler","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-010-2113-3","article-title":"Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials","volume":"215","author":"de Menezes","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","article-title":"A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder","volume":"66","author":"Montgomery","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib17","series-title":"Psychiatry Clin. Neurosci","article-title":"Generalized social anxiety disorder: a still-neglected anxiety disorder 3 decades since Liebowitz\u05f3s review","author":"Nagata","year":"2015"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1745-0179-2-35","article-title":"Resistant social anxiety disorder response to escitalopram","volume":"2","author":"Pallanti","year":"2006","journal-title":"Clin. Pract. Epidemol. Ment. Health"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/JCP.0b013e31829a878b","article-title":"Open-label treatment with escitalopram in patients with social anxiety disorder and fear of blushing","volume":"33","author":"Pelissolo","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.02.013_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11011-012-9280-3","article-title":"Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram","volume":"27","author":"Warwick","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.euroneuro.2016.02.013_bib22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T19:54:41Z","timestamp":1536954881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0924977X16000675"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.02.013","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}